Trained immunity in bone marrow progenitors as driver of atherosclerosis in obesity.

Completed

Conditions: Cardiovascular disease
obesity
10003216

Registration Number: NL-OMON49754

Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 60

Inclusion Criteria

-Participant in 300OB cohort, so all have a BMI> 27 and age >18 years
-Males
-Written informed consent
-4 weeks prior to inclusion stop cholesterol lowering drugs such as: statins

Exclusion Criteria

-Inability to personally provide written informed consent (e.g. for linguistic
or mental reasons)
-Documented bleeding diathesis or thrombocytopenia <50 *10e9/L
-History of haematological malignant disease
-Current treatment for maligancy
-Acute or chronic infections at the time of participation
-Medical history of any disease associated with immune deficiency (either
congenital or acquired, including chemotherapy, chronic steroid use, organ
transplant)
-Clinically significant infections within 1 months prior to study entry
(defined as fever >38.5)
-Previous vaccination within 1 months prior to study entry
-Chronic use of anti-inflammatory drugs such as NSAIDs (acetylsalicylic acid
<100 mg/day excluded)

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The most important question is whether there is trained immunity in the bone<br /><br>marrow progenitor cells of the subjects with the metabolic syndrome compared to<br /><br>subjects without metabolic syndrome. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The two other study parameters are 1) whether there are characteristics of<br /><br>trained immunity in the circulating monocytes, and 2) whether there is<br /><br>heterogeneity in the circulating monocytes with respect to the trained<br /><br>phenotype. </p><br>